Originally published by our sister publication Infectious Disease Special Edition
Before 2021, oral medication was the only option for HIV prevention and treatment, but adherence has always been a challenge. Now patients can get long-acting bimonthly injections in place of a daily pill, but this regimen presents new difficulties.
Long-acting cabotegravir (CAB-LA; Apretude, ViiV Healthcare) for pre-exposure prophylactic (PrEP) and cabotegravir-rilpivirine (CAB/RPV; Cabenuva, ViiV)